Get the Stockscreener App
9.46
6.77%
0.60
After Hours:
9.46
Cvrx Inc stock is traded at $9.46, with a volume of 154.02K.
It is up +6.77% in the last 24 hours and up +15.93% over the past month.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$8.86
Open:
$8.84
24h Volume:
154.02K
Relative Volume:
0.45
Market Cap:
$248.91M
Revenue:
$56.65M
Net Income/Loss:
$-53.31M
P/E Ratio:
-4.6277
EPS:
-2.0442
Net Cash Flow:
$-40.75M
1W Performance:
+11.16%
1M Performance:
+15.93%
6M Performance:
+17.22%
1Y Performance:
-22.65%
1-Day Range:
$8.84
$9.71
1-Week Range:
$8.47
$9.84
52-Week Range:
$4.2993
$13.15
Cvrx Inc Stock (CVRX) Company Profile
Name
Cvrx Inc
Sector
Industry
Phone
(763) 416-2850
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
9.46 | 233.12M | 56.65M | -53.31M | -40.75M | -2.0442 |
ABT
Abbott Laboratories
|
102.67 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.59 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.65 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.75 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-14-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-10-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-24 | Reiterated | Lake Street | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| May-01-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Lake Street | Buy |
| Jul-18-22 | Initiated | Craig Hallum | Buy |
| Jul-26-21 | Initiated | Canaccord Genuity | Buy |
| Jul-26-21 | Initiated | Piper Sandler | Overweight |
| Jul-26-21 | Initiated | William Blair | Outperform |
View All
Cvrx Inc Stock (CVRX) Latest News
Patterns Watch: Is CVRX a speculative investmentPortfolio Profit Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Sectors Review: Is CVRX a strong candidate for buy and holdInsider Buying & Technical Analysis for Trade Confirmation - baoquankhu1.vn
IMA,CVRX Volatility & Greeks - Finviz
How (CVRX) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
CVRx touts Barostim therapy as improving exercise capacity in heart failure beyond GDMT alone - Traders Union
SGP,CVRX Volatility & Greeks - Finviz
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CVRx, Inc. (CVRX) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-03-26 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CVRx, Inc. (CVRX) And Encourages Shareholders to Reach Out | NDAQ:CVRX | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
CVRx, Inc. (NASDAQ:CVRX) Q4 2025 earnings call transcript - MSN
CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
IMA,CVRX Dividends - Finviz
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Investors to Connect - ACCESS Newswire
CVRx’s BENEFIT-HF Trial: New Heart Failure Study Sets Up a Key Catalyst for Investors - tipranks.com
Bronstein, Gewirtz & Grossman, LLC Encourages CVRx, Inc. (CVRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
CVRx Inc Stock (ISIN: US12674F1003) Gains Momentum on Heart Failure Device Adoption Amid Medtech Sec - AD HOC NEWS
Sentiment Review: Will CVRX benefit from government policy2026 Price Swings & Precise Buy Zone Identification - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
EPS Watch: How is CVRx Inc managing supply chain issuesOptions Play & Daily Stock Momentum Reports - baoquankhu1.vn
Trading Systems Reacting to (CVRX) Volatility - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Stockholders to Connect - ACCESS Newswire
Securities Fraud Investigation Into CVRx, Inc. (CVRX) Continues – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz - The AI Journal
FinancialContentCVRx, Inc. (CVRX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - FinancialContent
Levels Update: Whats the beta of CVRx Inc stock2026 Pullbacks & High Conviction Investment Ideas - baoquankhu1.vn
First Barostim procedure at Ascension Alexian Brothers backed by CVRx - Traders Union
CVRx (CVRX) CMO granted 62K options, 41K RSUs and sells 1.3K shares - Stock Titan
Exit Recap: Will CVRx Inc announce a stock splitMarket Rally & Long-Term Growth Plans - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
CVRx, Inc. (NASDAQ:CVRX) Sees Significant Increase in Short Interest - MarketBeat
IMA,CVRX Options - Finviz
Bronstein, Gewirtz & Grossman, LLC Encourages CVRx, Inc. (CVRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CVRx, Inc. (CVRX) And Encourages Investors to Reach Out - ACCESS Newswire
CVRx enables first Barostim implant at Baptist Medical Center expanding heart failure treatment options - Traders Union
Buybacks Report: Does CVRx Inc meet Warren Buffetts criteria2026 PreEarnings & Precise Buy Zone Tips - baoquankhu1.vn
CVRx outlines $55M-$57M revenue target for 2025 as sales force transition nears completion - MSN
CVRX SEC FilingsCvrx, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Energy Moves: Why is CVRx Inc stock going downMarket Sentiment Review & Smart Allocation Stock Reports - baoquankhu1.vn
CVRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
CVRx shares rise on CMS inclusion for Barostim implant procedure - MSN
CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates - MSN
Quarterly Earnings: Is CVRx Inc. stock affected by interest rate hikesTrade Risk Summary & High Return Stock Watch Alerts - Naître et grandir
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How Cvrx Inc. (CVRX) Affects Rotational Strategy Timing - Stock Traders Daily
Risk Check: Whats the beta of CVRx Inc stock2025 Macro Impact & Weekly High Return Stock Forecasts - baoquankhu1.vn
Barostim device transforms life after severe heart failure, CVRx asserts - Traders Union
Trend Recap: Why is CVRx Inc stock going downPortfolio Return Summary & Safe Capital Growth Trade Ideas - baoquankhu1.vn
CVRX Earnings History & Surprises | EPS & Revenue Results | CVRX INC (NASDAQ:CVRX) - ChartMill
CVRx to present late-breaking THT2026 data in clinical webinar - Traders Union
CVRx Introduces New Performance-Based Executive Stock Unit Plan - The Globe and Mail
CVRx (CVRX) lists Chief HR Officer Gregory Morrison as insider on Form 3 - Stock Titan
CVRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cvrx Inc Stock (CVRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cvrx Inc Stock (CVRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hykes Kevin | PRES & CEO |
Mar 02 '26 |
Sale |
7.90 |
7,763 |
61,349 |
284,237 |
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,284 |
10,146 |
60,551 |
| OASHEIM JARED | CHIEF FINANCIAL OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,744 |
13,781 |
96,703 |
| John Robert Allen | Chief Revenue Officer |
Mar 02 '26 |
Sale |
7.90 |
3,964 |
31,326 |
86,036 |
| Jain Mudit K. | Director |
Feb 20 '26 |
Buy |
6.36 |
46,800 |
297,592 |
980,183 |
| Jain Mudit K. | Director |
Feb 18 '26 |
Buy |
4.64 |
600 |
2,785 |
5,650 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 26 '25 |
Sale |
10.03 |
6,337 |
63,560 |
4,040,861 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 24 '25 |
Sale |
10.06 |
2,200 |
22,132 |
4,047,198 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 21 '25 |
Sale |
10.00 |
500 |
5,000 |
4,049,398 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 12 '25 |
Sale |
10.00 |
1,000 |
10,000 |
4,049,898 |
2.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):